e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:07/Issue:04/April-2025 Impact Factor- 8.187 www.irjmets.com

TEIXOBACTIN: A REVOLUTIONARY ANTIBIOTIC FOR COMBATTING DRUG RESISTANT PATHOGENS

Nikita D Kale*1, Sakshi R Khatal*2, Nikita S Kapkar*3, Ankit P Dere*4, Pavan A Kadlag*5, Rushikesh G Kasar*6

*1,2,3,4,5,6Student, Amrutvahini College Of Pharmacy, Sangamner, Maharashtra, India.

ABSTRACT

The global rise in antibiotic-resistant bacteria has created an urgent need for novel antimicrobial agents. Teixobactin, a recently discovered antibiotic, has emerged as a promising solution due to its unique mechanism of action and resistance-resistant properties. Derived from Eleftheria terrae through iChip technology, teixobactin effectively targets Gram-positive bacteria by binding to highly conserved precursors of cell wall biosynthesis, such as Lipid II and Lipid III. Unlike conventional antibiotics, it does not act on bacterial proteins, making the development of resistance highly unlikely. This review explores the discovery, structure, mechanism of action, antimicrobial spectrum, pharmacokinetics, resistance profile, and future prospects of teixobactin. Challenges in its clinical translation, including issues related to synthesis, formulation, and spectrum expansion, are also discussed [1,2].

Keywords: Teixobactin, Antibiotic Resistant Bacteria, Ichip Technology, Lipid II & Lipid III.

I. INTRODUCTION

Antimicrobial resistance (AMR) has emerged as a major global health threat, leading to the failure of standard antibiotic therapies and increased mortality rates. According to the World Health Organization (WHO), multidrug-resistant (MDR) pathogens are responsible for an estimated 1.27 million deaths annually [3]. The stagnation in antibiotic discovery over the past decades has contributed to the crisis, necessitating the identification of new antimicrobial compounds with novel targets and resistance-resistant mechanisms [4].

Teixobactin, discovered in 2015 by Ling et al., represents a paradigm shift in antibiotic development [5]. It is the first antibiotic identified using the iChip cultivation technique, which enables the growth of previously unculturable soil bacteria. Teixobactin exhibits potent activity against drug-resistant Gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecium, and Clostridioides difficile. Importantly, no spontaneous resistance to teixobactin has been observed, making it a highly promising candidate for clinical application [6].

II. DISCOVERY AND STRUCTURAL CHARACTERISTICS

Discovery via iChip Technology

Traditional methods of antibiotic discovery rely on culturable bacteria, which represent only a small fraction of microbial diversity. The iChip, an innovative cultivation device, allows for the growth of unculturable bacteria by simulating their natural environment [7]. Using this technique, researchers isolated Eleftheria terrae, a previously unknown bacterium, which produced teixobactin [8]. This discovery marked a breakthrough in antibiotic research by expanding the pool of microbial sources for new drugs.

Chemical Structure

Teixobactin is a cyclic depsipeptide composed of 11 amino acid residues, including non-ribosomal amino acids and unusual components such as L-allo-enduracididine. Its structure is characterized by a lipid tail, which plays a crucial role in binding to bacterial cell wall precursors. The cyclic nature of teixobactin contributes to its stability and bioactivity, distinguishing it from linear peptides [9].

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:07/Issue:04/April-2025 Impact Factor- 8.187 www.irjmets.com



Figure 1: Chemical Structure of Teixobactin.

III. MECHANISM OF ACTION

Teixobactin exerts its bactericidal effect by targeting cell wall synthesis, a pathway essential for bacterial survival. Unlike traditional antibiotics that inhibit enzymes, teixobactin binds directly to peptidoglycan precursors, preventing cell wall assembly [10].

Inhibition of Peptidoglycan and Teichoic Acid Biosynthesis

- Teixobactin binds to **Lipid II**, a crucial precursor for peptidoglycan synthesis, thereby blocking bacterial cell wall formation [11].
- It also targets **Lipid III**, which is essential for teichoic acid synthesis, a structural component necessary for Gram-positive bacterial integrity [12].
- By disrupting these processes, teixobactin causes bacterial lysis and death [13].



Absence of Resistance Development

- Most antibiotics act on bacterial proteins, which can mutate to confer resistance. Teixobactin, however, binds to highly conserved molecules that bacteria cannot easily modify [14].
- In laboratory studies, no resistance has emerged even after prolonged exposure to teixobactin, suggesting a low likelihood of resistance development in clinical settings [15].

IV. ANTIMICROBIAL SPECTRUM AND EFFICACY

Gram-Positive Pathogens

Teixobactin demonstrates potent activity against a range of Gram-positive bacteria, including:

- Methicillin-resistant Staphylococcus aureus (MRSA) [16]
- Vancomycin-resistant Enterococcus (VRE) [17]
- Clostridioides difficile (a major cause of hospital-acquired infections) [18]
- Bacillus anthracis (the causative agent of anthrax) [19]
- Mycobacterium tuberculosis (the bacterium responsible for tuberculosis) [20]

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:07/Issue:04/April-2025 Impact Factor- 8.187 www.irjmets.com

Limited Activity Against Gram-Negative Bacteria

- Gram-negative bacteria possess an outer membrane that prevents teixobactin from reaching its target sites [21].
- However, efforts to modify teixobactin's structure to enhance its penetration into Gram-negative bacteria are ongoing [22].

V. PHARMACOKINETICS AND RESISTANCE PROFILE

Pharmacokinetics and Bioavailability

- Teixobactin exhibits **strong tissue penetration** and a **long half-life**, suggesting favorable pharmacokinetics [23].
- It is currently administered **intravenously**, but research is ongoing to develop oral formulations [24].
- The compound has shown **low toxicity** in preclinical studies, making it a promising candidate for therapeutic use [25].

VI. CONCLUSION

Teixobactin represents a major breakthrough in antibiotic discovery, offering a novel mechanism of action and a high barrier to resistance development. Its efficacy against MDR Gram-positive pathogens makes it a promising candidate for future clinical use. However, challenges related to formulation, bioavailability, and production must be addressed before teixobactin becomes a widely available therapeutic agent. Continued research into synthetic modifications and clinical applications will be essential to unlocking the full potential of this groundbreaking antibiotic.

VII. REFERENCES

[1] Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schaberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K. "A new antibiotic kills pathogens without detectable resistance." Nature. 2015 Jan 22;517(7535):455-459. https://doi.org/10.1038/nature14098

[2] World Health Organization. "Antimicrobial resistance: global report on surveillance." WHO Press. 2014. https://www.who.int/publications/i/item/9789241564748

[3] O'Neill J. "Tackling drug-resistant infections globally: final report and recommendations." Review on Antimicrobial Resistance. 2016. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf

[4] Lewis K. "Platforms for antibiotic discovery." Nature Reviews Drug Discovery. 2013 May;12(5):371-387. https://doi.org/10.1038/nrd3975

[5] Hover BM, Kim SH, Katz M, Charlop-Powers Z, Owen JG, Ternei MA, Maniko J, Estrela AB, Molina H, Park S, Perlin DS, Brady SF. "Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens." Nature Microbiology. 2018 Feb;3(4):415-422. https://doi.org/10.1038/s41564-018-0110-1

[6] Schroeder M, Brooks BD, Brooks AE. "The complex relationship between virulence and antibiotic resistance." Genes. 2017 Jan;8(1):39. https://doi.org/10.3390/genes8010039

[7] Epstein S. "The phenomenon of microbial uncultivability." Current Opinion in Microbiology. 2013 Oct;16(5):636-642. https://doi.org/10.1016/j.mib.2013.08.003

[8] Lewis K. "The science of antibiotic discovery." Cell. 2020 Jul 23;181(1):29-45. https://doi.org/10.1016/j.cell.2020.02.056

[9] Müller A, Wenzel M, Strahl H, Grein F, Saaki TN, Kohl B, Siersma T, Bandow JE, Sahl HG, Schneider T, Hamoen LW. "Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains." Proceedings of the National Academy of Sciences. 2016 Feb 16;113(45):E7077-E7086. https://doi.org/10.1073/pnas.1611173113

[10] Wright GD. "Something old, something new: revisiting natural products in antibiotic drug discovery." Canadian Journal of Microbiology. 2014 Jul;60(3):147-154. https://doi.org/10.1139/cjm-2014-0063

[11] Fleming A. "On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae." British Journal of Experimental Pathology. 1929 Jun;10(3):226-236. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2048009/

[12] Hiramatsu K. "Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance." The Lancet Infectious Diseases. 2001 Oct;1(3):147-155. https://doi.org/10.1016/S1473-3099(01)00144-9

[13] Livermore DM. "Bacterial resistance: origins, epidemiology, and impact." Clinical Infectious Diseases. 2003 Jan 15;36(Supplement_1):S11-S23. https://doi.org/10.1086/344654

[14] Projan SJ. "Why is big Pharma getting out of antibacterial drug discovery?" Current Opinion in Microbiology. 2003 Oct;6(5):427-430. https://doi.org/10.1016/j.mib.2003.08.003

[15] Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schaberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K. "A new antibiotic kills pathogens without detectable resistance." Nature. 2015 Jan 22;517(7535

[16] Wilson DN. "Ribosome-targeting antibiotics and mechanisms of bacterial resistance." Nature Reviews Microbiology. 2014 Jan;12(1):35-48. https://doi.org/10.1038/nrmicro3152

[17] Ling LL, Conlon BP, et al. "Teixobactin kills bacterial pathogens without detectable resistance." Nature. 2015;517(7535):455-459. https://doi.org/10.1038/nature14098

[18] Zgurskaya HI, Löpez CA, Gnanakaran S. "Permeability barrier of Gram-negative cell envelopes and approaches to bypass it." ACS Infectious Diseases. 2015 Jul;1(11):512-522. https://doi.org/10.1021/acsinfecdis.5b00097

[19] Parmar A, Lakshminarayanan R, et al. "Antimicrobial peptides targeting cell membranes: Current progress and future perspectives." Progress in Lipid Research. 2019 Jan;74:100788. https://doi.org/10.1016/j.plipres.2019.100788

[20] Zhou Q, Liu Q, Yang Z, et al. "Structure-activity relationships of teixobactin analogues." Frontiers in Microbiology. 2021 Feb;12:637057. https://doi.org/10.3389/fmicb.2021.637057

[21] Molloy EM, Field D, et al. "Teixobactin resistance: Mechanisms and implications for drug development." The Journal of Antibiotics. 2022 Jun;75(6):412-420. https://doi.org/10.1038/s41429-022-00536-5

[22] Newman DJ, Cragg GM. "Natural products as sources of new drugs over the nearly four decades from 1981 to 2019." Journal of Natural Products. 2020 Mar;83(3):770-803. https://doi.org/10.1021/acs.jnatprod.9b01285

[23] McBride SM, Sonenshein AL. "The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile." Microbiology. 2011 Jan;157(6):1457-1465. https://doi.org/10.1099/mic.0.046748-0

[24] Roemer T, Schneider T, Pinho MG. "Auxiliary factors: A chink in the armor of MRSA resistance to β-lactam antibiotics." Current Opinion in Microbiology. 2013 Oct;16(5):538-548. https://doi.org/10.1016/j.mib.2013.06.016

[25] Elsayed SS, Trusch F, et al. "Natural product discovery in the age of genomics." Natural Product Reports. 2020 Feb;37(1):115-129. https://doi.org/10.1039/C9NP00035A